Matching-adjusted indirect treatment comparison of guselkumab and ixekizumab in patients with moderate-to-severe psoriasis

被引：0
|
作者：
Varu, Abhishek [1 ]
Cameron, Chris [1 ]
Diels, Joris [2 ]
Hutton, Brian [3 ]
McElligott, Sean [4 ]
Schubert, Agata [5 ]
van Sanden, Suzy [2 ]
Villacorta, Reggie [4 ]
机构：
[1] Cornerstone Res Grp, Miamisburg, OH USA
[2] Janssen Pharmaceut, Beerse, Belgium
[3] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[4] Janssen Res & Dev, Raritan, NJ USA
[5] Janssen Cilag, Beerse, Belgium
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
6717
引用
收藏
页码：AB187 / AB187
页数：1
相关论文
共 50 条
  • [1] COMPARATIVE EFFICACY OF GUSELKUMAB AND TILDRAKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Van, Sanden S.
    Diels, J.
    Schubert, A.
    Barthelmes, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S410 - S410
  • [2] Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab
    Warren, R. B.
    Brnabic, A.
    Saure, D.
    Langley, R. G.
    See, K.
    Wu, J. J.
    Schacht, A.
    Mallbris, L.
    Nast, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1064 - 1071
  • [3] MATCHING-ADJUSTED INDIRECT COMPARISON OF GUSELKUMAB VERSUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: CHANGE IN BASELINE PASI FROM WEEK 4-40
    Sanyal, C.
    Situ, A.
    Alulis, S.
    Hassan, F.
    Peterson, S.
    Lee, J.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S206 - S206
  • [4] Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40
    Langley, Richard G.
    Sanyal, Chiranjeev
    Situ, Aaron
    Alulis, Sarah
    Hassan, Fareen
    Peterson, Steve
    Teneralli, Rachel E.
    Lee, Jennifer
    Patel, Barkha P.
    Disher, Tim
    [J]. JAAD INTERNATIONAL, 2024, 15 : 165 - 167
  • [5] Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
    Hampton, Philip
    Borg, Emma
    Hansen, Jes Birger
    Augustin, Matthias
    [J]. PSORIASIS-TARGETS AND THERAPY, 2021, 11 : 123 - 131
  • [6] Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Torres, Tiago
    Petersen, Anne Sohrt
    Ivens, Ulla
    Vilaro, Albert Bosch
    Stinson, John
    Carrascosa, Jose Manuel
    [J]. DERMATOLOGY AND THERAPY, 2024, 14 (04) : 983 - 992
  • [7] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Christopher J. Edwards
    Ruta Sawant
    Vishvas Garg
    Ella X. Du
    Alan Friedman
    Keith A. Betts
    [J]. Rheumatology and Therapy, 2021, 8 : 167 - 181
  • [8] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Edwards, Christopher J.
    Sawant, Ruta
    Garg, Vishvas
    Du, Ella X.
    Friedman, Alan
    Betts, Keith A.
    [J]. RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 167 - 181
  • [9] Matching-adjusted indirect comparison of efficacy of ixekizumab versus secukinumab through 1 year in pediatric patients with severe plaque psoriasis
    Prajapati, Vimal H.
    Swanson, Lisa
    Jossart, Christian
    See, Kyoungah
    Garrelts, Alyssa
    Ardekani, Gholamreza S.
    Chao, Yan-Cheng
    Lansang, Perla
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB193 - AB193
  • [10] Indirect comparison of ixekizumab versus risankizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis
    Gottlieb, Alice B.
    Ramot, Yuval
    Smith, Saxon D.
    Saure, Daniel
    Schuster, Christopher
    Schacht, Alexander
    Thaci, Diamant
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB226 - AB226
12345